Trial Profile
An Open-label, Randomised, Single-dose, Parallel-group Study to Demonstrate Bioequivalence of Two Formulations and the Effect of Food and Water on One Formulation of Lamotrigine in Healthy Male and Female Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Lamotrigine (Primary)
- Indications Bipolar disorders; Epilepsy
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 07 Sep 2007 Status changed from initiated to completed.
- 18 May 2007 New trial record.